Oxalic acid, monoamide, N-allyl-, pentyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Oxalic acid, monoamide, N-allyl-, pentyl ester
• 英文别名: pentyl 2-oxo-2-(prop-2-enylamino)acetate
• 化学式: C₁₀H₁₇NO₃
• 分子量: 199.25
• InChiKey: FFTIZGGACSULNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
  申请人：Das Kumar Saibal

  公开号：US20050096331A1

  公开（公告）日：2005-05-05

  The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel alkyl carboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

  本发明涉及新型抗糖尿病、降脂、抗肥胖和降胆固醇化合物，它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。更具体地，本发明涉及一般式(I)的新型烷基羧酸、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。
• Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
  申请人：DR. REDDY'S RESEARCH FOUNDATION AND REDDY- CHEMINOR, INC.

  公开号：US20020077320A1

  公开（公告）日：2002-06-20

  Novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the formula (I) and compositions containing them. 1 The compounds have hypolipidemic, antihyperglycemic uses.

  小说&bgr;-芳基-&agr;-氧基取代烷基羧酸的化学式(I)和含有它们的组合物。这些化合物具有降脂、降血糖的用途。
• Use of dual H3/M2 antagonists in the treatment of cognition deficit disorders
  申请人：Schering Corporation

  公开号：US20020151565A1

  公开（公告）日：2002-10-17

  This invention relates to a method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H 3 receptor antagonist/m 2 muscarinic antagonist, or a combination of a histamine H 3 receptor antagonist and a m 2 muscarinic antagonist.

  本发明涉及一种治疗认知缺陷症的方法，包括向需要治疗的哺乳动物施用有效量的双组胺 H 3 受体拮抗剂/组胺 2 毒蕈碱拮抗剂，或组胺 H 3 受体拮抗剂和 m 2 毒蕈碱拮抗剂的组合。
• USE OF DUAL H3/M2 ANTAGONISTS WITH A BIPIPERIDINIC STRUCTURE IN THE TREATMENT OF COGNITION DEFICIT DISORDERS
  申请人：SCHERING CORPORATION

  公开号：EP1408965A2

  公开（公告）日：2004-04-21
• US5641795A
  申请人：——

  公开号：US5641795A

  公开（公告）日：1997-06-24